Open Label Extension to Assess the Safety of Long-Term Treatment With Ampion for Severe Osteoarthritis (OA) of the Knee

PHASE3TerminatedINTERVENTIONAL
Enrollment

94

Participants

Timeline

Start Date

December 8, 2017

Primary Completion Date

October 4, 2018

Study Completion Date

October 4, 2018

Conditions
Severe Osteoarthritis of the Knee
Interventions
BIOLOGICAL

4 mL injection of AMPION™

4 mL injection of AMPION™

Trial Locations (11)

29406

Coastal Carolina Center at Lowcountry Orthopaedics, North Charleston

30060

Drug Studies America, Marietta

35205

Central Research Associates, Inc., Birmingham

60406

Healthcare Research Netword, Blue Island

63042

Healthcare Network Research, Hazelwood

67207

Heartland Research Associates, Wichita

78745

Tekton Research, Austin

91360

Westlake Medical Research, Thousand Oaks

92024

CORE Orthopaedic Medical Center, Encinitas

92835

St. Joseph Heritage, Fullerton

98007

Northwest Clinical Research Center, Bellevue

Sponsors
All Listed Sponsors
lead

Ampio Pharmaceuticals. Inc.

INDUSTRY

NCT03349645 - Open Label Extension to Assess the Safety of Long-Term Treatment With Ampion for Severe Osteoarthritis (OA) of the Knee | Biotech Hunter | Biotech Hunter